Avian influenza A viruses differ in their virulence and their ability to replicate in the lower respiratory tracts of squirrel monkeys (3, 7) . Previously, we evaluated the ability of three different avian influenza A viruses to serve as donors of attenuating genes to the wild-type human influenza A/Korea/ 1/82 (H3N2) virus (10) . We found a disassociation between the degree of virulence and the restriction of replication of the three avian influenza A viruses in squirrel monkeys and of their avian-human influenza A reassortant viruses in susceptible adult volunteers (10) . Avian-human reassortant viruses bearing the six internal RNA segments from the avian influenza A/Mallard/NY/6750/78 (H2N2), A/Pintail/ Alberta/119/79 (H4N6), and A/Mallard/Alberta/88/76 (H3N8) viruses (which replicated to low, intermediate, or high levels, respectively, in the lower respiratory tracts of squirrel monkeys [7] ) and the H3N2 surface glycoproteins of the virulent human influenza A/Korea/82 (H3N2) virus were similarly attenuated in adult volunteers. Compared with the other two avian-human influenza A reassortants, however, the avian-human influenza reassortant Nasal-wash specimens were collected for up to 10 days after virus inoculation from each volunteer who received the avian-human influenza A/Mallard/Alberta/76 reassortant virus, from 18 of 22 volunteers inoculated with 107-5 TCID50 of the avian-human influenza A/Mallard/NY/78 reassortant virus, and from each volunteer inoculated with wild-type virus. These specimens were used for isolation and quantitation of virus. Serum and nasal-wash specimens were collected before virus inoculation and 3 to 4 weeks after administration of the virus; these specimens were used to evaluate systemic and local respiratory tract antibody responses. The methods for virus isolation and the HAI antibody assay have been described previously (2, 5, 7). Influenza A/Mississippi/1/85 (H3N2) virus, which is serologically closely related to the influenza A/Bethesda/85 virus, was used as antigen in the HAI test because of its greater sensitivity in detecting serum antibody than the influenza A/ Bethesdal85 virus.
In addition, HA-specific immunoglobulin antibody in serum and HA-specific immunoglobulin A (IgA) antibody in nasal-wash specimens were measured concurrently by a kinetic-based enzyme-linked immunosorbent assay (KE-LISA) described elsewhere (8) . Purified HA from the influenza A/Mississippil85 virus (provided by Michael Phelan, Center for Drugs and Biologics, Food and Drug Administration, Bethesda, Md.) was used as the antigen in the KE-LISA. Briefly, the reagents consisted of HA, which was absorbed to the plate in carbonate buffer followed by single dilutions of serum (1:4,000 and 1:16,000) or nasal-wash specimen (1:64), immunoglobulin class-specific rabbit antihuman IgG (for serum) or IgA (for nasal wash) antibodies, goat anti-rabbit IgG antibody conjugated with alkaline phosphatase, and substrate. After the addition of substrate, each well of the 96-well plate was read by a Vmax Kinetic microplate reader (Molecular Devices, Palo Alto, Calif.). The rate of color development (milli-optical density units per minute) was calculated as the slope of the regression line defined by the optical density readings for that well. A 1.8-fold change in KELISA rates between preinoculation and postinoculation serum specimens and a 2.9-fold change in KELISA rates between preinoculation and postinoculation nasal-wash specimens were considered significant antibody responses, as described elsewhere (8) .
Dose-response studies revealed that the 50% human infec- Table 2) . After challenge with the wild-type human influenza A virus, 3 (30%) of the 10 unvaccinated control volunteers developed influenzalike illness. In contrast, both of the avian-human influenza A reassortant viruses were relatively nonreactogenic; illness occurred in only one vaccinee. This person, who received 1075 TCID50 of the avian-human influenza A/Mallard/Alberta/76 reassortant virus, had fever, myalgia, chills, nausea, and abdominal cramps that began 7 h after vaccination and lasted only 1 day. The ill vaccinee did not shed virus but did mount serum and nasal-wash HAspecific antibody responses after vaccination. Volunteers infected with the reassortant viruses shed significantly less virus over a shorter interval than did individuals infected with wild-type human influenza A virus ( In summary, the present study has demonstrated that each avian donor virus confers a similar set of properties on wild-type human influenza A virus. Considered in the context of previous studies (9; Sears et al., in press), our results suggest that the avian influenza A/Mallard/AlbertaI76 virus offers no clear advantage over the avian influenza A/Mallard/ NY/78 virus as a donor of attenuating genes for construction of live influenza virus vaccines for use in humans. For this reason, we have decided to restrict future evaluation of live attenuated influenza A vaccine candidates in children and high-risk populations to reassortants derived from the wellcharacterized avian influenza A/Mallard/NY/78 virus.
